Early relapses after adjuvant chemotherapy suggests primary chemoresistance in diffuse gastric cancer

S Pattison; C Mitchell; S Lade; T Leong; RA Busuttil; A Boussioutas

Journal article

Early relapses after adjuvant chemotherapy suggests primary chemoresistance in diffuse gastric cancer

S Pattison, C Mitchell, S Lade, T Leong, RA Busuttil, A Boussioutas

Plos One | PUBLIC LIBRARY SCIENCE | Published : 2017

DOI: 10.1371/journal.pone.0183891

Open access

Download PDF

Abstract

Background: Survival from gastric cancer remains poor, particularly in Western populations. Previous pre-clinical and subgroup analyses of clinical trials have suggested differing benefits from fluoropyrimidine-based chemotherapeutics for diffuse and intestinal gastric cancer. This analysis examines patterns of relapse with and without adjuvant chemotherapy after curative resection for gastric cancer in these subtypes to explore the Lauren classification as a predictive marker of benefit for fluoropyrimidine-based adjuvant chemotherapy. Patients and methods: Gastric cancer patients enrolled in an ongoing tissue banking study were analysed, 164 patients who would currently be considered for a..

View full abstract

University of Melbourne Researchers

A/Prof Catherine Mitchell Author

Prof Trevor Leong Author

Related Projects (2)

Gastric cancer: Early detection of disease, relapse and prediction of extent of diasease

Gastric cancer (GC) is the second commonest cause of cancer in the world. The mainstay of treatment for GC is surgical resection, but despit..

Establishment of a biomarker to test molecular risk of Gastric Cancer

Less than 20% of patients live 5 years after a diagnosis of gastric cancer (GC). This is due to the advanced stage at the time of diagnosis...

Grants

Awarded by National Health and Medical Research Council

Funding Acknowledgements

Collection and curation of the study cohort has been funded through a number of grants National Health and Medical Research Council (NHMRC) project grants (2004-2006 ID288714; 2007-2009 ID454584); 2009-2011 Cancer Australia ID570996; 2012-2014 Peter Mac Foundation grant ID APP1030980. S Pattison was supported a NHMRC post-graduate scholarship APP1039393. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.